

Q8  
35. (Once Amended) Method as claimed in claim 23 wherein,  
examination of developmental abnormalities using gain-of-function genetic model for  
human APC to study biochemical function of human APC function.

36. (Once Amended) Method as claimed in claim 23 wherein,  
examination of developmental abnormalities using gain-of-function genetic model for  
human APC to identify additional components of *Drosophila* Wnt/Wg signaling pathway.

**REMARKS**

Applicants respectfully request that the foregoing amendments be made prior to  
examination of the present application. The amendments are made to correct multiple  
dependencies and do not change the scope of the invention.

Respectfully submitted,

Date April 3, 2002

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407  
Facsimile: (202) 672-5399

By

Bernhard D. Saxe  
Attorney for Applicants  
Registration No. 28,665

**MARKED UP VERSION OF AMENDED CLAIMS**

4. (Once Amended) A method for selecting a compound for pharmacological activity, which potentially inhibits or enhances the developmental abnormalities induced by the expression of full length and protein domains of human APC in *Drosophila*, said method comprising:

- (a) providing the [first, second, and third] transgenic fly of claim[s] 1, [2 and 3 respectively] wherein said flies have said developmental abnormalities,
- (b) administering the said compounds to the said transgenic *Drosophila* at different concentrations, and
- (c) screening for changes in the severity of the phenotype.

5. (Once Amended) A method of determining various *Drosophila* proteins interacting with full-length and protein domains human APC protein wherein, said method comprising:

- (a) providing the [first, second, and third] transgenic fly of claim[s] 1,[2 and 3 respectively,] wherein said flies have said developmental abnormalities,
- (b) crossing the said transgenic flies individually to a set of *Drosophila* strains each of which carries mutation in a different gene or set of genes, and
- (c) screening for the change in the severity of the phenotype.

6. (Once Amended) A method for determining the modulation and differential expression of genes following the mis-expression of full-length and its protein domains human APC in *Drosophila* wherein, said method comprising:

(a) providing the transgenic *Drosophila* as claimed in claim[s] 1[,2 and 3] wherein, the flies have developmental abnormalities,

(b) screening for differential gene expression using differential display-RT PCR or microarray techniques, and

(c) identifying genes that are differentially regulated on expression of human APC.

9. (Once Amended) Method[s] as claimed in claim[s] 6 [-8] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC to study mechanism of various developmental processes such as wing, leg, eye, antennae, and adult cuticle development.

13. (Once Amended) Method[s] as claimed in claim[s] 6 [ - 8] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC which has advantages to study the *Drosophila* Wnt/Wg signaling pathway.

15. (Once Amended) A Method as claimed in claim[s] 5 [and 7] wherein, new target proteins interacting with  $\beta$ -catenin are identified.

17. (Once Amended) Method[s] as claimed in claim[s] 5 [ - 8] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC to study biochemical function of human APC function.

18. (Once Amended) Method[s] as claimed in claim[s] 5 [ - 8] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC to identify additional components of *Drosophila* Wnt/Wg signaling pathway.

22. (Once Amended) A method for selecting a compound for anti-cancer activity, which potentially inhibits or enhances the developmental abnormalities induced by the expression of full length and protein domains of human APC in *Drosophila*, said method comprising:

- (a) providing the [first, second, and third] transgenic fly of claim[s] 19,[20, and 21 respectively] wherein said flies have said developmental abnormalities,
- (b) administering the said compounds to the said transgenic *Drosophila* at different concentrations, and

- (c) screening for the change in the severity of the phenotype.

23. (Once Amended) A method of determining various *Drosophila* proteins interacting with full-length and protein domains human APC protein wherein, said method comprising:

- (a) providing the [first, second, and third] transgenic fly of claim[s] 19, [20, and 21 respectively] wherein said flies have said developmental abnormalities,
- (b) crossing the said transgenic flies individually to a set of *Drosophila* strains each of which carries mutation in a different gene or set of genes, and
- (c) screening for the change in the severity of the phenotype.

24. (Once Amended) A method for determining the modulation and differential expression of genes following the mis-expression of full-length and its protein domains human APC in *Drosophila* wherein, said method comprising:

- (a) providing the transgenic *Drosophila* as claimed in claim[s] 19 [,20, and 21] wherein, the flies have developmental abnormalities,
- (b) screening for differential gene expression using differential display-RT PCR or microarray techniques, and
- (c) identifying genes that are differentially regulated on expression of human APC.

25. (Once Amended) A method for determining the modulation and differential expression of proteins following the mis-expression of full-length and its protein domain human APC in *Drosophila* wherein, said method comprising:

- (a) providing the transgenic *Drosophila*, as claimed in claim[s] 19 [, 20, and 21] wherein, the flies have developmental abnormalities,

(b) identifying differential gene expression and protein modifications using proteomics techniques, and

(c) identifying gene products that are differentially regulated on expression of human APC.

26. (Once Amended) A method to study Wnt/Wg signaling in *Drosophila* said method comprising;

(a) providing the transgenic *Drosophila*, as claimed in claim[s] 19 [ - 21],

(b) crossing these transgenic flies to a number of GAL4 drivers to induce targeted expression of said constructs in various tissues and at different developmental stages, and

(c) examining developmental abnormalities.

27. (Once Amended) Method[s] as claimed in claim[s] 24 [ - 26] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC to study mechanism of various developmental processes such wing, leg, eye, antennae, and adult cuticle development.

31. (Once Amended) Method[s] as claimed in claim 24 [ - 26] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC which has advantages to study the *Drosophila* Wnt/Wg signaling pathway.

33. (Once Amended) Method[s] as claimed in claim[s] 23 [and 25] wherein, new target proteins interacting with  $\beta$ -catenin are identified.

35. (Once Amended) Method[s] as claimed in claim[s] 23 [ - 26] wherein, examination of developmental abnormalities using gain-of-function genetic model for human APC to study biochemical function of human APC function.

36. (Once Amended) Method[s] as claimed in claim[s] 23 [ - 26]  
wherein, examination of developmental abnormalities using gain-of-function genetic  
model for human APC to identify additional components of *Drosophila* Wnt/Wg signaling  
pathway.